Dispense Sample Clauses

Dispense. The placing of one or more doses of a prescribed medication into containers that are correctly labeled to indicate the name of the offender, the contents of the container, and all other vital information.
Sample 1Sample 2
AutoNDA by SimpleDocs
Dispense approximately 1 mL of REP Prep onto the left side of the rectangle on the electrophoresis chamber floor.
Sample 1Sample 2
Dispense. [Confidential Treatment Requested] of sample into [Confidential Treatment Requested] coated tube 2. Add [Confidential Treatment Requested] solution and vortex 3. Incubate for [Confidential Treatment Requested] 4. Aspirate and wash [Confidential Treatment Requested] with wash solution 5. Add [Confidential Treatment Requested] of [Confidential Treatment Requested] solution 6. Incubate for [Confidential Treatment Requested] 7. Aspirate and wash [Confidential Treatment Requested] 8. Measure tubes for [Confidential Treatment Requested] in [Confidential Treatment Requested] Limit of detection: [Confidential Treatment Requested] TgAb activity Precision: [Confidential Treatment Requested] CV intra-assay over range Range: [Confidential Treatment Requested] U/ml IMMUNOCHEMILUMINOMETRIC ASSAY FOR THYROID PEROXIDASE ANTIBODIES INTRODUCTION Autoimmune thyroid disease is characterized by the production of antibodies to various thyroid proteins. Thyroid peroxidase (TPO) is one such protein and the detection of circulating antibodies to TPO is indicative of thyroid autoimmunity.
Sample 1
Dispense pharmaceutical drugs to Xxxxxx Health Fund members that provide coherent prescription and membership details in line with the Xxxxxx Health Fund plans as denoted either on the members’ card or on the Holistic Insurance Platform (HiP) portal. The two generic plans are FUND and MAIN / SCHEME
Sample 1
Dispense. [Confidential Treatment Requested] test sample or control into each well
Sample 1
Dispense. [Confidential Treatment Requested] of serum sample into tube 2) Add [Confidential Treatment Requested] of receptor solution 3) Incubate [Confidential Treatment Requested] at [Confidential Treatment Requested] 4) Add [Confidential Treatment Requested] of [Confidential Treatment Requested] labeled [Confidential Treatment Requested] solution 5) Incubate [Confidential Treatment Requested] 6) Add [Confidential Treatment Requested] solution, vortex 7) Centrifuge for [Confidential Treatment Requested] at [Confidential Treatment Requested] 8). Aspirate supernatant 9) Resuspend pellet in [Confidential Treatment Requested] deionized water 10) Measure tubes for [Confidential Treatment Requested] in [Confidential Treatment Requested] Limit of detection: [Confidential Treatment Requested] TRAb activity Precision: [Confidential Treatment Requested] intra-assay over range Range: [Confidential Treatment Requested] U/ml SCHEDULE B Page ___ SCHEDULE B UWCM PATENTS CASE WCM 3: LUMINESCENT PROTEIN LABELING COUNTRY PATENT # FILED PRIORITY EXPIRY ------- -------- ----- -------- ------ GB 2008247B 14/11/78 17/11/77 14/11/98 Canada 1113392 16/11/78 17/11/77 01/12/98 Germany 2849708 16/11/78 17/11/77 Lapsed Switzerland 640061 13/11/78 17/11/77 13/11/98 France 7832459 17/11/78 17/11/77 17/11/98 USA 4478817 14/11/78 17/11/77 23/10/01 CASE WCM 3 (DIVISIONAL) HOMOGENEOUS ASSAY COUNTRY PATENT # FILED PRIORITY EXPIRY ------- -------- ----- -------- ------ GB 2095830B 01/11/81 17/11/77 14/11/98 Germany 2858792 07/06/89 17/11/77 17/11/98 Switzerland 645725 13/12/83 17/11/77 13/11/98 Canada 1116079 27/3/81 17/11/77 12/01/99 CASE WCM 13: ACRIDINIUM LABELS COUNTRY PATENT # FILED PRIORITY EXPIRY ------- -------- ----- -------- ------ GB 2112779B 08/12/82 11/12/81 08/12/02 Europe* 0082636 08/12/82 11/12/81 08/12/02 USA# 4946958 26/09/88 11/12/81 07/08/07 CASE WCM 16: MASS PHOTON IMMUNOASSAY COUNTRY PATENT # FILED PRIORITY EXPIRY ------- -------- ----- -------- ------ GB 2129553B 09/09/83 10/09/82 09/09/03 Europe** 0103469 09/09/83 10/09/82 09/09/03 USA 4761382 05/02/87 10/09/82 02/08/05 Japan Pending 29/12/83 10/09/82 29/12/03 *France, Germany, Holland, Switzerland **Belgium, France, Germany, Italy, Holland, Switzerland UWCM PATENT APPLICATIONS #US Continuation Applications 08/328563 filed 24/10/94 and 08/455414 filed 31/05/95 are still pending. BIOANALYSIS PATENTS None BIOANALYSIS PATENT APPLICATIONS None
Sample 1
Dispense about 1 mL of REP Prep onto the left side of the marked area of the chamber.
Sample 1
AutoNDA by SimpleDocs
Dispense. Dispense Pharmaceuticals as set out in Orders utilizing one of the following types of packaging: (i) blister cards for all oral, solid dosage forms (tablets and capsules), including utilization of Unit Dose packaging where required for the return and re-use of Pharmaceuticals; (ii) liquid, oral medications will be dispensed in bulk form unless another format is mandated by the appropriate PHS medical staff and agreed upon between Maxor and PHS; (iii) injectable medications; and (iv) special packaging as requested by the appropriate PHS medical staff and agreed upon by Maxor.
Sample 1
Dispense approximately 1 mL of REP Prep onto the cathode (left) side of the electrophoresis chamber.
Sample 1

Related to Dispense

  • Prescription Claims against the Issuer or any Guarantor for the payment of principal or Additional Amounts, if any, on the Notes will be prescribed ten years after the applicable due date for payment thereof. Claims against the Issuer or any Guarantor for the payment of interest on the Notes will be prescribed five years after the applicable due date for payment of interest.

  • Labeling Upon request, Lessee will xxxx the Equipment indicating Lessor's interest with labels provided by Lessor. Lessee will keep all Equipment free from any other marking or labeling which might be interpreted as a claim of ownership.

  • Medication 1. Xxxxxxx’s physician shall prescribe and monitor adequate dosage levels for each Client.

  • Packages a. CLIENT has purchased one or more of the following packages (the “Package”) as Full Season, Single Game or Bundled Packages from TAILGATE GUYS as reflected in the order placed with TAILGATE GUYS by CLIENT and incorporated herein by reference upon payment therefore:

  • Samples Physical examples of materials, equipment, or workmanship that are representative of some portion of the Work and that establish the standards by which such portion of the Work will be judged. The Contractor shall furnish for approval all samples required by the Contract Documents. The Work shall be in accordance with approved samples.

  • Prescription Glasses This plan covers prescription glasses as follows: • Frames - one (1) collection frame per plan year; • Lenses - one (1) pair of glass or plastic collection lenses per plan year. This includes single vision, bifocal, trifocal, lenticular, and standard progressive lenses. This plan covers the following lens treatments: • UV treatment; • tint (fashion, gradient, and glass-grey); • standard plastic scratch coating; • standard polycarbonate; and • photocromatic/transitions plastic. Contact Lenses (in lieu of prescription glasses) This plan covers one (1) supply of contact lenses as follows: • conventional contact lenses - one (1) pair per plan year from a selection of provider designated contact lenses; or • extended wear disposable lenses - up to a 6-month supply of monthly or two- week single vision spherical or toric disposable contact lenses per plan year; or • daily wear disposable lenses - up to a 3-month supply of daily single vision spherical disposable contact lenses per plan year. This plan also covers the evaluation, fitting, or follow-up care related to contact lenses. This plan covers additional contact lenses if your prescribing network provider submits a verification form, with the regular claim form, verifying that you have one of the following conditions: • anisometropia of 3D in meridian powers; • high ametropia exceeding -10D or +10D in meridian powers; • keratoconus when the member’s vision is not correctable to 20/25 in either or both eyes using standard spectacle lenses; and • vision improvement for members whose vision can be corrected two lines of improvement on the visual acuity chart when compared to the best corrected standard spectacle lenses.

  • Food Although food may be served at a program being paid for with grant funds, the food may not be purchased with grant or matching funds.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

  • Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

  • Medications Psychotropic medications and medications associated with treating a diagnosed mental health condition.

Time is Money Join Law Insider Premium to draft better contracts faster.